How Much Does Your Life Cost w/ Stuart Berkowitz
Send us Fan Mail
Most teams in pharma say they want breakthrough impact, yet R&D portfolios keep clustering around the familiar. That tension is where our conversation with Stuart Berkowitz gets practical fast: if a disease area is already “98% served” by existing interventions, why sink a decade into a new molecule that barely moves the needle?
We dig into how biology is changing shape as a field, from wet lab routines to computational biology, bioinformatics, and system-level thinking. Stuart shares stories from genomics funding and even engineered microbes, then uses those examples to…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.